ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bidding Requirements

ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutics company, today announced that the Company has received a written notice (the “Notification letter“) of Nasdaq Global Market LLC (“Nasdaq“) on August 19, 2024, indicating that the Company does not meet the minimum bid price requirement set forth in Nasdaq Rule 5450(a)(1) based on the fact that the closing bid price of the Company’s common stock was less than US$1.00 per share for the 30 consecutive business days from July 5, 2024 through August 15, 2024.

The notice letter is merely a notice of default, not a notice of impending delisting, and has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq at this time.